Display options
Cite
Bergenstal RM, Forti A, Chiasson JL, et al. Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). Diabetes Ther. 2012;3(1):13doi: 10.1007/s13300-012-0013-8.
Bergenstal, R. M., Forti, A., Chiasson, J. L., Woloschak, M., Boldrin, M., & Balena, R. (2012). Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). Diabetes therapy : research, treatment and education of diabetes and related disorders, 3(1), 13. https://doi.org/10.1007/s13300-012-0013-8
Bergenstal, Richard M, et al. "Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial)." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 3,1 (2012): 13. doi: https://doi.org/10.1007/s13300-012-0013-8
Bergenstal RM, Forti A, Chiasson JL, Woloschak M, Boldrin M, Balena R. Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). Diabetes Ther. 2012 Dec;3(1):13. doi: 10.1007/s13300-012-0013-8. Epub 2012 Nov 09. PMID: 23138449; PMCID: PMC3508113.
Copy Download .nbib Format: NLM
Share it on

Diabetes Ther. 2012 Dec;3(1):13. doi: 10.1007/s13300-012-0013-8. Epub 2012 Nov 09.

Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial).

Diabetes therapy : research, treatment and education of diabetes and related disorders

Richard M Bergenstal, Adriana Forti, Jean-Louis Chiasson, Michael Woloschak, Mark Boldrin, Raffaella Balena

Affiliations

  1. Park Nicollet International Diabetes Center, Minneapolis, MN, 55416, USA, [email protected].

PMID: 23138449 PMCID: PMC3508113 DOI: 10.1007/s13300-012-0013-8

Abstract

INTRODUCTION: The efficacy and safety of taspoglutide, a long-acting human glucagon-like peptide-1 analog, were compared with sitagliptin or placebo, as adjunct to metformin, in patients with inadequately controlled type 2 diabetes.

METHODS: In this randomized, double-blind, double-dummy, parallel-group trial, patients were randomized to taspoglutide 10 mg once weekly (QW), 20 mg QW, 100 mg sitagliptin once daily (QD), or placebo for 24 weeks, followed by 28-week short-term and 104-week long-term extension periods. The primary endpoint was change in glycosylated hemoglobin (HbA(1c)) after 24 weeks.

RESULTS: In this study, 666 patients (baseline HbA(1c), 7.96% [SD, 0.87]; fasting plasma glucose, 9.61 mmol/L [2.56]; body weight, 92.4 kg [19.3]) were randomized to taspoglutide 10 mg QW (n = 190), 20 mg QW (n = 198), 100 mg sitagliptin QD (n = 185), or placebo (n = 93) for 24 weeks. After 24 weeks, least squares mean (SE) HbA(1c) reductions were greater with taspoglutide 10 mg (-1.23% [0.06]) and 20 mg (-1.30% [0.06]) versus sitagliptin (-0.89% [0.06]) or placebo (-0.10% [0.08]). Mean treatment differences with taspoglutide 10 mg and 20 mg were -0.34 (95% confidence intervals [CI]: -0.49, -0.19) and -0.41 (-0.56, -0.26) versus sitagliptin; and -1.13 (-1.31, -0.95) and -1.20 (-1.38, -1.02) versus placebo. Weight loss was greater with taspoglutide 10 mg (-1.8 kg [0.3]) and 20 mg (-2.6 kg [0.3]) than sitagliptin (-0.9 kg [0.3]) or placebo (-0.5 kg [0.4]). Effects on HbA(1c) and weight loss continued through 52 weeks of treatment. No cases of severe hypoglycemia occurred with any active treatment. Gastrointestinal adverse events, and allergic and injection-site reactions were higher in the taspoglutide groups, causing higher discontinuation rates. Anti-taspoglutide antibodies were confirmed in 46% of patients.

CONCLUSION: Taspoglutide demonstrated better efficacy on glycemic control and weight loss than sitagliptin, but a high incidence of adverse events led to high discontinuation rates. The safety profile of taspoglutide in this trial was similar to other trials in the clinical program, and led to the discontinuation of dosing.

References

  1. Diabetes Care. 2006 Dec;29(12):2638-43 - PubMed
  2. JAMA. 2007 Jul 11;298(2):194-206 - PubMed
  3. Diabetes Care. 2010 Jun;33(6):1255-61 - PubMed
  4. Diabet Med. 2009 Mar;26(3):268-78 - PubMed
  5. Lancet. 2010 Apr 24;375(9724):1447-56 - PubMed
  6. Drugs. 2005;65(3):385-411 - PubMed
  7. Diabetes Obes Metab. 2011 Jan;13(1):65-74 - PubMed
  8. Diabetes Care. 2005 May;28(5):1092-100 - PubMed
  9. Lancet. 2009 Jul 4;374(9683):39-47 - PubMed
  10. Diabetes Care. 2007 Jun;30(6):1487-93 - PubMed
  11. Diabet Med. 2010 May;27(5):556-62 - PubMed
  12. Lancet. 2010 Aug 7;376(9739):431-9 - PubMed
  13. Diabetes Obes Metab. 2007 Sep;9 Suppl 1:23-31 - PubMed
  14. Diabetes Obes Metab. 2008 Nov;10(11):994-1003 - PubMed
  15. Curr Med Res Opin. 2008 Feb;24(2):537-50 - PubMed
  16. Diabetes Care. 2009 Jan;32(1):84-90 - PubMed
  17. Lancet. 2010 Jun 26;375(9733):2234-43 - PubMed
  18. Diabetes Obes Metab. 2012 Jun;14(6):546-54 - PubMed
  19. Lancet. 2008 Oct 4;372(9645):1240-50 - PubMed
  20. Diabetes Metab Res Rev. 2011 Sep;27(6):528-42 - PubMed
  21. Diabet Med. 2009 Nov;26(11):1156-64 - PubMed
  22. Diabetes Care. 2009 Jul;32(7):1237-43 - PubMed
  23. Diabetes Care. 2009 Jul;32(7):1224-30 - PubMed

Publication Types